

5-minute health questionnaire reviewed by a licensed physician within 24 hours.

If approved, your physician creates a personalized protocol tailored to your health profile.

Pharmacy-compounded medications shipped directly to your door with COA included.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) with FDA approval history for reducing visceral adipose tissue. It stimulates the pituitary gland to produce growth hormone, which in turn promotes lipolysis (fat breakdown) — particularly in visceral fat stores. Clinical studies demonstrated up to 18% reduction in visceral fat with consistent use. Unlike direct GH, tesamorelin maintains physiologic GH pulsatility and has a well-characterized safety profile.


All medications carry potential risks. Common side effects of Tesamorelin may include:
This is not a complete list of side effects. Your prescribing physician will discuss protocol-specific risks during your consultation. Report any adverse reactions immediately.
Tesamorelin has FDA approval history for specific indications (HIV-associated lipodystrophy). The compounded version prescribed through pepta is prepared by a licensed 503A pharmacy and is not an FDA-approved finished product.
Clinical studies showed up to 18% visceral fat reduction. Individual results vary based on adherence, diet, exercise, and baseline body composition. Your physician will set realistic expectations.
Most studies measured outcomes at 26 weeks. Patients may notice body composition changes within 8-12 weeks. Consistency is key.
Tesamorelin is most effective when combined with a healthy diet and regular exercise. Your physician may provide lifestyle guidance alongside your protocol.